Published in Cancer Weekly, November 14th, 2006
The company and its 21 employees will now operate as part of a newly created wholly owned subsidiary of Endo Pharmaceuticals Inc.
The transaction includes an up-front payment of up to $20 million, with the potential for up to an additional $95 million in earn-out payments based on clinical development...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.